Peer Review Committee for Leukemia, Immunology and Blood Cell Development (LIB)

Areas Reviewed

Basic, preclinical, and clinical applications involving aspects of of immunologic therapies of
cancer and modulation of immune responses to cancer including:

  • active and passive immune therapies for cancer
  • adoptive transfer of autologous or allogeneic hematopoietic cells
  • targeted delivery of toxic payloads
  • immune tolerance
  • hematologic malignancies  including leukemia and lymphoma
  • hematopoiesis
  • molecular, structural, biochemical and biophysical aspects of the immune system including cell types, cytokines, antigen processing, antibody molecules, and deficiencies

Committee Members

Jose Guevara-Patino, MD, PhD, Chair
Loyola University, Chicago
Maywood, IL

Ellen Beswick, PhD
University of New Mexico Health Science Center
Albuquerque, NM

Subbarao Bondada, PhD
University of Kentucky
Lexington, KY

Jianjun Chen, PhD
University of Cincinnati
Cincinnati, OH

Patrick Gaines, Stakeholder
Aurora, CO

Stephen Gottschalk, MD
Baylor College of Medicine
Houston, TX

Michael Gough, PhD
Providence Portland Medical Center
Portland, OR

Karen Haas, PhD
Wake Forest University
Winston Salem, NC

Amir Jazaeri, MD
University of Texas, MD Anderson Cancer Center
Houston, TX

Amy Johnson
Ohio State University
Columbus, OH

Kay Kays, Stakeholder
Sun City, AZ

Guangyong Peng, MD, PhD
Saint Louis University
Saint Louis, MO

Neha Reddy Pidatala, Stakeholder
New York, NY

Iryna Pinchuk, PhD
University of Texas Medical Branch, Galveston
Galveston, TX 

Kathryn Schwertfeger, PhD
The Regents of the University of Minnesota – Twin Cities
Minneapolis, MN 

Padmanee Sharma, MD, PhD
The University of Texas, MD Anderson Cancer Center
Houston, Texas

Zhenglun (Jerry) Zhu, MD, PhD
Brigham and Women’s Hospital
Boston, MA

Sandra Zinkel, MD, PhD
Vanderbilt University
Nashville, TN